![Rashid Sayyid: RW study of LuPSMA in VISION-eligible mCRPC patients](https://oncodaily.com/pub/uploads/2024/06/Pi7_Tool_1662993262608-e1718045495912.jpg)
Photo from Rashid Sayyid/X
Jun 11, 2024, 22:40
Rashid Sayyid: RW study of LuPSMA in VISION-eligible mCRPC patients
Rashid Sayyid, Urologic Oncology Clinical Fellow at University of Toronto, shared a post on X:
“RW study of LuPSMA in VISION-eligible mCRPC patients from expanded access program (UCLA, UCSF, Tulane, Johns Hopkins; n=117) compared to VISION phase 3 results.
- RW patients more likely to have received >1 ARPI (70% versus 46%), have worse PS, and have LN disease
- Similar OS (15.1) and PSA50 (42%)
- Increased incidence of Gr3+ lymphopenia in RW (34% versus 8%)
Results support use of LuPSMA in RW setting.”
Source: Rashid Sayyid/X
Aug 13, 2024, 14:45